Multinomial phase II cancer trials incorporating response and early progression.

  title={Multinomial phase II cancer trials incorporating response and early progression.},
  author={Benny Chung Ying Zee and David Melnychuk and Janet E. Dancey and Elizabeth Eisenhauer},
  journal={Journal of biopharmaceutical statistics},
  volume={9 2},
The objective of a phase II clinical trial in oncology is to assess the antitumor activity of a specific treatment regimen. A multiple-testing procedure is commonly used to decide whether the experimental treatment warrants further investigation based on patients' tumor response. There are ethical concerns about exposing patients to a new drug when the response rate is low and a relatively large number of patients have early progressive disease. Ensign et al. (1) proposed a stopping rule that… CONTINUE READING

From This Paper

Topics from this paper.


Publications citing this paper.
Showing 1-10 of 24 extracted citations

Performance of multinomial designs in comparison with response-based designs in non-randomized phase II trials of targeted cancer agents.

Annals of oncology : official journal of the European Society for Medical Oncology • 2013
View 4 Excerpts
Highly Influenced

Impact of the 2010 Consensus Recommendations of the Clinical Trial Design Task Force of the NCI Investigational Drug Steering Committee.

Clinical cancer research : an official journal of the American Association for Cancer Research • 2015
View 1 Excerpt

Interleukin-21 has activity in patients with metastatic melanoma: a phase II study.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology • 2012

Similar Papers

Loading similar papers…